Individualized treatment rules (ITRs) tailor treatments according to individual patient characteristics. They can significantly improve patient care, and are thus becoming increasingly popular. Data collected during randomized clinical trials are often utilized for estimating the optimal ITRs. However, these trials are generally expensive to run, and, moreover, are not designed for the purpose of efficiently estimating ITRs. In this paper, we propose a costeffective estimation method from an active learning perspective. In particular, our method only recruits the "most informative" patients (in terms of learning the optimal ITRs) from an ongoing clinical trial. Simulation studies and real data examples show significant improvements of our active clinical trial method over competing methods. Risk bounds are derived and shown to support these observed empirical advantages.
Introduction
It is widely recognized that patients benefit differently from the same treatment. Recent advances in personalized medicine have shown promise for improving treatment decisions in clinical practice by tailoring the clinical interventions to patient characteristics; these characteristics include demographics, medical histories, genetic or genomic information and so on (Hamburg and Collins, 2010) . It is anticipated that these new developments in personalized medicine may salvage some failed medications (Woodcock, 2007; Hamburg and Collins, 2010) , which is especially important given the recent low overall success rate of clinical trials (DiMasi et al., 2010) .
The success of personalized medicine is contingent on correct identification of the best treatments for each individual. One direction is to perform subgroup analysis, where patients are grouped based on the estimated individual-level treatment differences (Cai et al., 2011; Foster et al., 2011) . Alternatively, there is vigorous research focusing on finding optimal treatment regimens, which yield the greatest benefit overall for the whole population. Some methods involve fitting a regression model for the response, and recommending patients with the treatment achieving the best prediction (Qian and Murphy, 2011) . Instead, Zhao et al. (2012) explore the optimal individualized therapies from a classification perspective (see also Zhang et al. (2012) ). All the aforementioned methods are implemented using the data from randomized clinical trials (RCTs). However, these traditional RCTs are primarily designed to confirm the efficacy of new treatments, but not for generating comprehensive personalized therapy rules in an efficient manner. Consequently, post-mining data from RCTs is not ideal for finding optimal treatment strategies (Cui et al., 2002; Lagakos, 2006) . Moreover, they generally require a large sample size to demonstrate sufficient efficacy of a candidate treatment, and can be expensive to run due to the need to treat and monitor a large number of subjects. Therefore, it would be desirable to design cost-effective clinical trials for personalized medicine, where individual differences in response are highlighted, and continuing advances revealed in the trial are taken advantage of (Singer, 2005) .
We propose an active learning framework for conducting clinical trials, called as active clinical trials. In this trial, patients are judiciously recruited such that the optimal ITRs could be learned with less patients being randomized, i.e., a cost-effective method. Within the classification framework (Zhao et al., 2012) , we first construct "confidence intervals" for the optimal decision boundary using the data accumulated so far based on either frequentist or Bayesian approach, and then selectively enroll the patients whose optimal treatments are hard to determine, i.e., the benefit differences from different treatments are "small", based on the above constructed confidence intervals. Those patients are viewed as the most informative ones for learning the optimal ITRs, and thus recruited into randomized treatments in the next stage. Some other adaptive enrichment designs (Wang et al., 2009; Simon and Simon, 2013) share similar spirit as the proposed active clinical trials, given that they allow the eligibility criteria to be updated overtime during the trial. The proposed new clinical trial paradigm, along with the analysis and inference tool, are different in the sense that we primarily aims to construct informative and favorable ITRs instead of confirming the efficacy of one treatment over another. As will be seen in the empirical and theoretical analysis, the real-time selection of the right patients indeed improves the chance of discovering optimal ITRs with a drastically reduced sample size and cost.
In Section 2, we introduce a general methodology for conducting active clinical trials, along with the methods for constructing optimal ITRs using the resulting data. In Section 3, we discuss theoretical properties of the proposed approach by providing a finite sample upper bound on the difference in expected outcome under the estimated ITR and the optimal ITR.
We conduct extensive simulation studies to examine the empirical performances in Section 4. Two real data examples are provided in Section 5. Section 6 is devoted to the discussion of presented results.
Methodology

Optimal Individual Treatment Rule
In this section, we discuss a probabilistic framework for studying the optimal ITRs that is similar to Qian and Murphy (2011) and Zhao et al. (2012) . Let (X, A, R) be a random triple with a joint distribution P . Here, X ∈ R p denotes patient's baseline covariates with marginal distribution Π, A is a binary treatment assignment taking values in {−1, 1}, and R stands for the treatment outcome (a larger value of R corresponds to a better outcome).
An ITR D(·) is defined as a function from the covariate space R p into the treatment space
Our goal is to identify the optimal ITR that yields the maximum expected outcome. For any ITR D, let P D be the distribution of (X, A, R) when A = D(X), and denote E D as the corresponding expectation. The value of an ITR D, denoted by V (D), represents the expected outcome if it were implemented for the whole population in the future. Hence, we write the value function V (D) = E D (R). Qian and Murphy (2011) show that V (D) can be expressed as
where E denotes the expectation w.r.t. the joint distribution P , I(·) is an indicator function and π(a; X) is the conditional probability P (A = a|X) for a ∈ {−1, 1}. For simplicity, we assume a pure randomization scheme with equal probability for different assignments, i.e., π(a; X) = 1/2, throughout the paper.
Let D * denote the optimal treatment rule that maximizes V (D). By re-writing V (D) as
where f
optimal decision boundary is just the level set {x ∈ R p : f * (x) = 0}. As seen from above, the overall benefit will be maximized if the patients with biomarker levels satisfying f * (x) ≥ 0 receive alternative treatment (treatment 1), and the others receive standard care (treatment -1). Hence, the decision is tailored according to a patient's own characteristics characterized by some quantitative biomarker X.
To estimate the optimal ITR D * from the data see Zhao et al. (2012) for more details. All of the aforementioned methods take the whole (randomized) clinical trial data as an input, and thus have no influence on the data collection process, therefore, they belong to the class of passive learning methods. In clinical trials, it is known that the patient recruiting process usually has long duration, and the treatment and monitoring process can be extremely expensive. With a limited budget and fixed total sample size, we should wisely allocate the resources, e.g., decide who to recruit, in order to learn the optimal ITRs with less cost (Deng et al., 2011) . This motivates us to propose the novel active clinical trials that can identify the optimal ITRs with significantly reduced cost.
Active Clinical Trials
The active learning (AL) approach in the classification literature is shown to produce accurate classifiers using a significantly reduced number of label requests; see Balcan et al. (2008) ; Dasgupta et al. (2007); Castro and Nowak (2008) ; Koltchinskii (2010); Hanneke (2011); Minsker (2012) . Recall that the estimation of ITRs can be thought of as being a classification problem. For example, a patient with a small outcome given the assigned treatment could be misclassified potentially. In this paper, we take advantage of AL techniques to select the "most informative" patients based on a given pool of prognostic variables, and then only randomize the patients with these "informative" characteristics. The intuition behind this patient selection process is simple: if we have high confidence that certain patients will benefit from a particular treatment, we should not recruit them into the study since it is very likely that they will not contribute to the estimation of ITRs. On the other hand, we know that it is hard to determine the optimal treatment, i.e., the sign of f * (x), for a subset of patients if their baseline variables are "close" to the optimal decision boundary. As will be seen from the empirical and theoretical analysis, the patients with such features are more "informative" in the sense that their outcomes of the randomized treatments provide more insights about learning the optimal ITRs. Moreover, since patients will not be randomized for whom we have high confidence in the treatment they should receive, they are less likely exposed to inefficacious medications.
An algorithm of our active clinical trial design proceeds as follows:
1. Collect an independent and identically distributed (i.i.d.) sample S 0 = (X, A, R) (of small sample size) from P , and construct a preliminary estimator of f * ; repeat the following two steps until the the number of patients that can be randomized is reached:
2. Recruit a new patient with baseline variables X;
3. Construct a confidence interval for f * (X) based on the currently available sample:
(a) if the confidence interval does not contain 0: drop the patient from the study;
(b) if the confidence interval contains 0: randomize the patient into the treatment or the control group, record the outcome R, and add (X, A, R) into the current sample.
A more precise description is given in Algorithm 1 below. Also see figures 1 and 2 in Section 3 for graphical illustration.
Algorithm 1: Active Clinical Trials for Personalized Medicine input : Total sample size N for randomization, the limit kmax on the total number of participating individuals
for i = 1 to N 0 do /* collecting the initial sample */ Recruit X (i) from the marginal distribution Π; Randomize X (i) to treatment A (i) = 1 or −1 with equal probability;
end else Randomize X (k) to treatment A (k) = 1 or −1 with equal probability;
Observe the outcome
LB=LB-1; end end By implementing the above procedure, we obtain a data set containing "the most informative" observations for predicting the optimal treatment. For every new patient, this data set will be used to predict the treatment rule based on that individual's baseline variables.
At each iteration, an estimator of the contrast function and the corresponding confidence interval need to be specified. In the next section, we will propose two different construction methods based on kernel estimation and Gaussian process regression, respectively. We remark that the empirical performance of our method is essentially controlled by the confidence level we set in Step 3. This level also determines the rejection ratio, e.g., N = 100 out of k max = 140 in simulation Scenario 1 of Section 4.
Confidence Interval Construction
Kernel Smoothing Approach
Let K be a smooth kernel function (with the bandwidth h n ) satisfying Assumption (A2) in
, be the conditional expectation of R given A and X. Given n observations from P , we propose the following estimators η j (·; h n ) for j = ±1, and the plug-in estimator f (·; h n ) of the contrast function f * (·): at any fixed point x 0 ,
Here, h n = h n (x 0 ) is an adaptive bandwidth parameter varying with x 0 . We need to choose a proper h n (x 0 ), which controls the local amount of data near x 0 , for optimally balancing the estimation bias and variance; see Appendix A.3.2 for more technical details.
Assuming that both η 1 and η −1 are Lipschitz continuous with Lipschitz constants bounded by L, define
where C 1 (K, P ) is a constant depending on the kernel K and distribution P , and · 2 is the usual Euclidean norm. Set
This choice mimics the usual "bias-variance tradeoff": indeed, the bias of η j (x 0 ; h) is bounded by the order of Lh, while
plays the role of the variance parameter. Based on the above choice of h n (x 0 ), i.e., (2.4), we define the radius of the confidence interval as
where t controls the coverage probability. The display above depends on the unknown constants C 1 (K, P ) that has to be chosen before running the algorithm. Given a certain confidence level, we recommend to select the "confidence parameter" t by reverting the coverage probability error that decays exponentially fast with t; see Corollary A.1.
Remark 1. We are aware that the proposed kernel methods are unfortunately affected by the "curse of dimensionality". On the other hand, our subsequent theoretical analysis reveals that the empirical performance of our kernel estimate essentially depends on the "intrinsic dimension" d of the support of the marginal distribution Π, which might be lower than the ambient dimension p. See Assumption (A3) in Section 3. For example, the number of "large" principal components of baseline covariates d can be significantly smaller than the total number of covariates p.
Gaussian Process Regression Approach
The new method presented in this section is particularly well suited for applications since it is completely data-driven and does not require to specify any unknown parameters in advance; see its good practical performance in Section 4. However, the price is to assume that the conditional distribution of the outcome R given (A, X) is Gaussian. In other words, if an individual with baseline variables X receives treatment A = j, we assume that the outcome satisfies R = η j (X) + ε for j = ±1, where ε ∼ N (0, σ 2 ). In this situation, we take a Bayesian approach by imposing a Gaussian process prior (defined by the mean m(·) and covariance k(·, ·)) on functions η 1 (·) and η −1 (·); see Chapter 2 of Rasmussen and Williams (2006) . For simplicity, the mean function m(·) is set to be identically zero throughout this paper.
As before, the confidence interval of the contrast function builds upon those of η 1 (·) and η −1 (·). Hence, we start from the inference procedure for
i=1 be the observations corresponding to the individuals who received the treatment 1. The covariance function of the Gaussian process prior is set as a slight variant of the squared exponential kernel: given x = (x 1 , . . . , x p ) and
Under the Gaussian error assumption, the marginal distribution of the
) is a multivariate Gaussian with mean 0 and covariance matrix
from the data by finding a local maximum of the marginal log-likelihood
with respect to (γ 0 , . . . , γ p , σ 2 ); see Section 5.4.1 in Rasmussen and Williams (2006) for more details. Therefore, the Gaussian process regression is a global method that can automatically select the bandwidth by maximizing the data likelihood. This is in contrast with the previous kernel method that the bandwidth is selected locally; see equation (2.4) above.
We next construct the confidence interval based on the posterior distribution of η 1 (·) with the optimal Γ * . Given a new observation with the baseline variable x 0 , the value of η 1 (x 0 ) is then estimated by the posterior mean, denoted as η 1 (x 0 ), i.e.,
2 ) for x, x ∈ R p , and
The variance of the posterior distribution is given by
The square root of the posterior variance naturally controls the length of the confidence interval for η 1 (x 0 ): for example, setting δ 1 (x 0 ) := 3 σ 1 (x 0 ) gives the confidence interval for η 1 (x 0 ) of posterior probability > 99% (note that this may not correspond to the frequentist coverage).
Define η −1 (x 0 ) and the associated δ −1 (x 0 ) analogously. In the end, we obtain a confidence interval with the center f (
Numerical implementation of this Bayesian inference procedure can be easily performed with the gpml Matlab toolbox (Rasmussen and Nickisch, 2010) .
Theoretical Analysis
In this section, we focus our theoretical analysis on the kernel smoothing approach. We first introduce an important notion of active set (Minsker, 2012) , which underlies the majority of active learning algorithms. On each step k of our Algorithm 1, the active set AS k is defined as the set of baseline variables for which the best treatment is yet unknown. In particular, the active set is characterized by the confidence interval -i.e., x belongs to the active set if and only if the confidence interval for f * (x) contains both positive and negative elements;
see Figures 1 and 2 below. Note that the active set is only used in the future theoretical analysis, and does not need to be evaluated explicitly in Algorithm 1.
To perform the theoretical analysis, we need a slightly modified version of Algorithm 1 which builds on an explicit construction of the active set AS k . We call this version "Algorithm 2" whose exact formulation is presented in Appendix A. Active Set (Bold line)
Figure 2: X (1) belongs to the active set, X (2) does not.
For simplicity, we suppose that the marginal distribution Π of the baseline variable vector X is known. Note that Algorithm 1 does not need to know or estimate Π explicitly, and this assumption is only for theoretical analysis purpose. In addition, we assume the following conditions on the kernel K : R p → R and the distribution Π:
Lipschitz continuous on R p with Lipschitz constants bounded by L.
(A1) The random variable |R| is bounded by 0 < M < ∞ a.s.
(A3) "Intrinsic dimension" of supp(Π) is equal to d for some integer d ≤ p, and Π is equivalent to the uniform distribution over its support; see Appendix A.1 for a more precise statement.
Assumption (A3) says that over a "nice" set Π is close to the uniform distribution; see condition (A.1) in Appendix. The intrinsic dimension d is crucial here: in many applications, p is often large but d could be small (see Remark 1). Note that the rate in our main result, Theorem 3.1, depends only on d but not on p. Assumption (A4) is an analogue of the well-known margin condition (Tsybakov, 2004) which is commonly used to characterize the complexity of a binary classification problem. Larger values of γ mean that both treatment effects are less likely to be similar, yet in nontrivial examples, γ ∈ [0, d]. In particular, as indicated in Proposition 3.4 in Audibert and Tsybakov (2007) , for a smooth contrast function
does not cross 0 at any point in the interior of the supp(Π),
i.e., all patients benefit from one treatment. Note that our analysis does not require γ to be known in advance.
We are ready to present the (finite-sample) performance guarantee for our method.
Theorem 3.1. With probability greater than 1 − α, the estimator D of D * returned by Algorithm 2 satisfies
where N is the number of randomized treatments, θ =
and C is a constant that depends on the kernel K and distribution Π.
It is worth noting that when γ is large (say, close to d), the resulting rate of Theorem 3.1 is "almost" dimension-free. We also remark that the rate of Theorem 3.1 can not be uniformly improved by any active learning technique as shown in Minsker (2012) . As we estimate the optimal ITRs from a classification prospective, there is a direct analog between passive learning and active learning (for the binary classification) in statistical learning theory. In the passive learning setup, the corresponding rate could be much slower, as we comment below. Audibert and Tsybakov (2007) investigate the performance of the so-called plug-in estimators for binary classification in the passive learning setup, whereas Minsker (2012) addresses a similar question in the active learning framework. While the rigorous analysis of passive learning methods is beyond the scope of the present work, it can be shown that under assumptions of Theorem 3.1, the upper bound for the regret of an estimator in the passive learning scheme is N −(1+γ)/(2+d) (up to log-factors), in which the ITRs are constructed from a clinical trial without the selection of patients. This is shown to be optimal for a wide class of underlying distributions in Audibert and Tsybakov (2007) . Note that this rate is slower than the rate derived in Theorem 3.1.
Qian and Murphy (2011) used a parametric modeling approach, i.e., fitting a L 1 -penalized regression model to estimate the optimal ITRs, and they obtained a rate of (log N/N )
with an appropriate choice of tuning parameter. However, their model could be misspecified in practice. In contrast, our method is nonparametric with minimal model assumptions.
Simulation Studies
In this section, we to assess the empirical performance of the active clinical trial method. Let X = (X 1 , X 2 , . . . , X p ), where X 1 , . . . , X p are independent of each other. The distribution of X varies according to different scenarios detailed below. The treatment A is generated from {−1, 1} with equal probability. The response R is generated from N (Q 0 (X, A), 1), where 
3. p = 3, m 0 (X) = 1 + 2X 1 + X 2 − X 3 , T 0 (X, A) = 1.5(X 1 X 2 (1 + X 3 ))A, where X 1 , X 2 , X 3 are on the sphere generated as follows. Let X 1 , . . . , X 3 ∼ U [−1, 1], and
where
It can be seen that the optimal ITR for Scenario 1 is linear, i.e., D * (X) = sign(1 − X 1 − X 2 ). The optimal ITR for Scenario 2 is nonlinear, with
. Scenario 3 represents the case that data is supported on the manifold, i.e., a 2-dimensional sphere in R 3 . The treatment effect in Scenario 3 is highly nonlinear with D * (X) = sign(X 1 X 2 (1 + X 3 )). Scenario 4 considers a relatively high dimensional covariate, i.e., 8, with a linear treatment effect.
We apply the active clinical trial outlined in Algorithm 1. The kernel method in Section 2.3.1, denoted as 'AL-BV', and Gaussian process regression method in Section 2.3.2, denoted as 'AL-GP', were both implemented in the simulations. In particular, gpml Matlab toolbox (Rasmussen and Nickisch, 2010) was used in the latter method. The active clinical trial proceeds by selectively recruiting subjects whose differential treatment effects are smaller than certain threshold, i.e., Steps 3 -4 of the Algorithm 1. This iterative procedure screens out certain number of subjects, denoted as N , whose optimal treatments can be determined with high confidence, and the rest N subjects are retained for estimating the optimal ITR.
Hence, we have N + N subjects in total.
In addition, we compare with two passive learning approaches: outcome weighted learning (OWL) method (Zhao et al., 2012) , and ordinary least square (OLS) method. Both methods recruit subjects upon arrival during the clinical trial, and estimate the optimal ITR using the collected data after the trial ends. For a fair comparison, in each run, we randomly sample N subjects out of the total N + N patients. In the OWL method, using the available data from N subjects, we minimize the target function P n Rφ(A(β 0 + X T β))/π(A; X) + λ n β 2 2 , where φ(t) = max(1 − t, 0) is the hinge loss, P n denotes the empirical measure, and λ n is a tuning parameter controlling the amount of penalization. The optimal ITR can be estimated via
, where β 0 and β are the minimizers of the above objective function.
In the OLS method, we first regress R on (X, A, XA), and then estimate the optimal ITR by finding the treatment which yields a larger predicted outcome for each individual.
The initial sample size N 0 is fixed at 50, while the additional sample size N − N 0 varies from 50, 100, 200, 300, 400, 500 to 800. To evaluate the empirical performances, we generated a testing dataset of sample size 10000, mimicking a large pool of future subjects. The estimated ITRs D(X) using different methods are validated on this large testing set. Since the main effect is invariant across different ITRs, we can calculate the average excess value
where the empirical average is taken over the validation set. This quantity directly reflects the expected clinical benefits for future subjects treated according to D(X), with a smaller value indicating a better treatment decision. We repeat the process for 1000 times, and average the resulting values over all runs. In Figure 3 , we plot log{AEV (D * , D)} against log(N −N 0 ), where D was obtained using each method. The log-scale is assumed for providing a better display of the polynomial convergence rates in different methods. In all scenarios, our active clinical trials perform uniformly better than the OWL. In Scenario 1, the treatment effect is linear, which indicates that the OLS is the best possible method. However, our AL-GP method still has comparable performance, especially when the sample size is large.
The performance of AL-BV method is also improving over N . When the treatment effect is non-linear, as indicated in Scenarios 2 and 3, the strength of active learning is clearly demonstrated. Both methods initially perform better under small sample sizes, and then converge much faster as sample size grows. Conversely, the values of the estimated ITRs from the other two methods do not converge (Scenario 3), or at least do not converge to the optimal value (Scenario 2). In Scenario 4, the number of covariates is increased to 8.
This poses severe difficulties on the kernel estimation due to the curse of dimensionality.
Even under this setup, the performance of AL-BV is still comparable with the OWL. Again, with the linear treatment effect, AL-GP's results are satisfactory compared with the OLS.
Hence, we believe that active learning methods in general provide robust results to various treatment mechanisms, which are usually unknown in reality.
Real Data Analysis
Nefazodone-CBASP Clinical Trial
We apply the proposed active learning methods to analyze the data from the Nefazodone-CBASP clinical trial (Keller et al., 2000) . The randomized trial was conducted to compare the efficacy of three alternate treatments for non-psychotic chronic major depressive disorder (MDD), including Nefazodone, Cognitive Behavioral-Analysis System of Psychotherapy (CBASP) or the combination of Nefazodone and CBASP. CBASP requires twice-weekly onsite visits to the clinic, and thus imposes a significant burden on patients compared with
Nefazodone alone. Hence, we compare the Nefazodone with the combination treatment, and investigate whether CBASP is necessary for all patients. We perform a complete case analysis. The score on the 24-item Hamilton Rating Scale for Depression (HRSD) was the primary outcome, where higher scores indicate more severe depression. Data from 443 patients was 
Scenario 4
Additional Sample Size (log scale) Excess Values (log scale) AL−GP AL−BV OLS OWL available, with 210 and 221 patients were randomized to Nefazodone and the combined treatment group, respectively. We consider 3 covariates for tailoring treatment, including baseline HRSD scores, alcohol dependence and HAMA Somatic Anxiety Scores, where the latter two covariates were selected as being important variables for optimal treatment decision making in Gunter et al. (2007) .
For our methods, we set the initial sample size at 50, and then actively selected the patients until an additional 300 patients were recruited, or all patients were examined. 289 and 350 patients were used to constructed the optimal ITRs using AL-BV and AL-GP methods respectively, while all patients were used for OLS and OWL analysis. The estimated ITRs from different methods were applied to the whole data sets to calculate the average HRSD scores due to the ITRs, with smaller values being more preferable. 299 and 386 patients were recommended to the combination therapy by AL-BV and AL-GP methods, which lead to average HRSD scores of 8.75 and 9.95 respectively. Conversely, 430 patients were recommended to use the combined treatment from both OLS and OWL, which yield a higher score of 10.89. Hence, the treatment rules produced by active clinical trials not only lead to a higher overall benefit, but also reduce time and monetary burdens on patients.
We then used a 5 fold cross validation type analysis to avoid a potential impact of over fitting. The whole data set was partitioned into five subsets. 4 out of 5 subsets were used as the training data for constructing the optimal ITR, and the remaining subset was retained as the validation set for evaluating the estimated rule. In the training subsample, we applied both active learning and passive learning methods, i.e., OLS and OWL, to construct the optimal ITRs. The initial sample size was set at 50 for the proposed active learning methods. Figure 4 . The active learning methods lead to higher HRSD scores in the beginning, but they catch up and continue to improve as the sample size grows. In particular, we can see a faster decreasing pattern of the resulting HRSD scores from our methods. After the additional sample size reaches 120, with the total sample size at 170, the ITR identified by AL-BV method yields the lowest score over the other competing methods, and can be further improved with larger sample sizes. 
12-step Intervention on Stimulant Drug Use
The data comes from a randomized clinical trial, with the purpose to evaluate the effectiveness of an 8-week combined group plus individual 12-step facilitative intervention on stimulant drug use (Donovan et al., 2013) . Individuals with stimulant use disorders were randomly assigned to treatment as usual (TAU) or TAU into which the Stimulant Abuser Groups to Engage in 12-Step (STAGE-12) intervention was integrated.
The primary outcome variable of interest is the number of days of self-reported stimulant drug use across the 3-month to 6-month post-randomization period, where a smaller value would be preferable. We use 7 baseline variables to evaluate the patients and to construct the optimal ITR: age, the average number of days per month of self-reported stimulant drug use within 3 months prior to randomization, the baseline alcohol use, the drug use, the employment status, the medical status, and the psychiatric status composite scores, on the Addiction Severity Index (ASI), where the ASI composite score, ranging between 0 (no endorsement of any problems) and 1 (maximal endorsement of all problems), are usually measured in practice to indicate problem severity, and are perceived to guide the treatment decision (McGahan et al., 1986) .
After removing the missing data, we have 305 participants in total. We evaluated different methods on the whole data set, with initial sample size fixed at 50, and additional sample size set at 200. AL-BV and AL-GP methods recommended 123 and 90 patients to the STAGE-12 group, with the expected outcomes as 11.3 and 12 respectively. The OLS and OWL methods lead to overall averages of 11.8 and 12.7 days. We also calculated the crossvalidated number of days of drug use across the 3-month to 6-month post-randomization period. Since the outcome was count data, and indicated considerable zero-inflation, overdispersion and a non-linear trend, it is anticipated that the active learning method using bias-variance tradeoff for estimation leads to the best results. Indeed, as shown in Figure   5 , AL-BV outperforms all other methods with an overall fast decreasing trend. While the Gaussian assumption is severely violated in this example, AL-GP was still improving over sample sizes. We note that OLS and OWL do not improve much as the sample size grows.
Discussion
In this paper, we propose the active clinical trial with the goal to construct favorable ITRs using minimal costs. This new paradigm is distinct from the standard clinical trial framework which was invented to evaluate treatments. Along with the new designs, we also present new analysis and inference tools that are often practically useful and theoretically efficient. There are two important future directions we are pursuing: (i) a more general contrast function that can accommodate high dimensional covariate or discrete covariate; (ii) dynamic treatment regime for a sequence of treatment rules (Murphy, 2003; Lavori and Dawson, 2004; Robins, 2004; Moodie et al., 2007) . We explain the meaning of "intrinsic dimension" introduced in Assumption (A3) here. We say that supp(Π) possesses a tree decomposition T = {T i,j , i ≥ 1, j = 1 . . . J(i)} if 1. T 1,1 = supp(Π), and {T i,j } J(i) j=1 forms a disjoint partition of supp(Π) for all i ≥ 1.
Nested partition
4. Regularity: for any i ≥ 1, 1 ≤ j ≤ J(i) and 0 < r ≤ 2 −i the following holds: there
for some 0 < c 1 (Π) ≤ c 2 (Π) < ∞ which are independent of i, j. Here, B(x, r) is the Euclidean ball of radius r centered at x.
A simple example that gives a good intuition to the tree decomposition is the uniform distribution over the unit cube in R p . In this case, the tree decomposition is given by partitioning the unit cube into dyadic cubes and
A.2 Formal statement of Algorithm 2
We first define some necessary notation before presenting Algorithm 2. Let B i be the sigmaalgebra generated by the collection of sets {T i,j , j = 1, . . . , J(i)} (a partition of supp(Π) on the level i). For S ⊂ supp(Π) and a function f : R p → R, let f | S : S → R be the restriction of f onto S, and define f ∞,S = f | S ∞ := sup x∈S |f (x)|. Given δ > 0, set
as the conditional distribution on S, and set
Since Π is assumed to be known, we can directly compute Q h (x|S) now. Accordingly, we modify the original kernel estimate for η j , i.e., (2.3), as follows: let {(
sample from the conditional joint distribution of (X, A, R) given that X ∈ S, and set
Properties of these estimators will be discussed in Lemma A.1 below.
A.3 Properties of Kernel Estimate
A.3.1 Preliminaries
Let h > 0, S ∈ B j and h ≤ 2 −j , and define
We next study the upper and lower bounds of Q h,m (x|S) based on Assumptions (A1)-(A4).
Since K is bounded and compactly supported, there exists
Recall that c 1 , c 2 are defined in (A.1). Note that Assumption (A2) implies the following: ;
Randomize X (i,0) to treatment A (i,0) = 1 or −1 with equal probability;
Observe
while LB > 0 do Set the confidence band size as δ k = 4Ch k /* C is the constant from Lemma A.1 */;
AS k := x ∈ supp(Π) : ∃f 1 , f 2 ∈ F k−1 , sign(f 1 (x)) = sign(f 2 (x)) /* active set */;
Randomize X (i,k) to treatment A (i,k) = 1 or −1 with equal probability;
Observe R (i,k) ;
f := f k /* keeping track of the most recent estimator */; end end and
In what follows, we will set Q h (x|S) := Q h,0 (x) for brevity.
A.3.2 Some bounds for the kernel estimators
In this subsection, we derive basic concentration inequalities for the kernel estimators of
The following Corollary is immediate:
Corollary A.1. Set h n := {Π(S)(t + d log(n/Π(S)))/n} 1/(d+2) . Then, under assumptions of Lemma A.1, with probability ≥ 1 − 4e
where constant C is the same as in Lemma A.1.
Proof. We prove Lemma A.1 here. Below is the usual "bias-variance" decomposition
We start with a bound on the bias term. Note that for any
where c 3 , c 4 are defined in Section A.3.1. Recall that Q h,1 (x|S) is defined in (A.3).
Next, we will bound the stochastic term. Given ε > 0, let
k=1 be the minimal ε-net on S ∩ supp(Π), so that for any y ∈ S ∩ supp(Π) there exists 1 ≤ k(y) ≤ N (ε) such that
Lipschitz condition on η j implies that
and, since |R| ≤ M almost surely and K has Lipschitz constant L K ,
Fix 1 ≤ i ≤ N (ε). We will apply the Bernstein's inequality (e.g., Lemma 2.2.9 in (van der Vaart and Wellner, 1996) ) to estimate | η j (x i ; h) − E η j (x i ; h)|. Our assumptions imply that for all 1 ≤ i ≤ N ,
almost surely for all x ∈ S ∩ supp(Π). Moreover, (A.4) implies that
Bernstein's inequality implies that for all t > 0,
with probability ≥ 1 − 2e −t . Combined with the union over all 1 ≤ i ≤ N (ε) and noting Lemma A.2. Under the margin assumption (A4),
Proof. It is easy to see that
The rest of the argument repeats Lemma 5.1 in (Audibert and Tsybakov, 2007) .
A.4.2 Main proof
Our main goal is to control the size of the set act k defined by Algorithm 2. In turn, these bounds depend on the size of the confidence bands for f
is the number of iterations performed by the algorithm before termination.
Let N act k := N k · Π(act k ) be the number of labels requested on the k-th iteration of the algorithm. We first claim that the following bounds hold uniformly for all 1 ≤ k ≤ L with probability at least 1 − α:
. This claim will be proved later.
Let E be the event of probability ≥ 1 − α on which both inequalities of (A.8) hold, and assume that it occurs. Second inequality of (A.8) implies, together with the fact that
with probability ≥ 1 − α. If N is the maximum number of randomized treatments the algorithm is allowed to request, then
and one easily deduces that on the last iteration L we have
( A.9) Recall that N L is defined in Algorithm 2.
To obtain the risk bound of the theorem from (A.9), we apply Lemma A.2: , which together with (A.10) yields the final result.
It remains to show both inequalities of (A.8). We start with the bound on f k −f * ∞,act k . to get that with probability ≥ 1 − α/N ,
where h k is defined in Algorithm 2. It remains to integrate the bound with respect to the distribution of
The union bound over all 1 ≤ k ≤ L ≤ N gives the result.
Finally, we will prove the second inequality of (A.8), the bound for the size of the active sets act k . This is the place where assumption (A3) on the tree decomposition and margin assumption (A4) play the key role. To obtain the bound, we will compare two estimators of f * : the first is the kernel estimator f k constructed by the Algorithm 2 on step k, and the second is the piecewise-constant estimatorf k with similar approximation properties to f k . Namely,f k is the L 2 (Π) -projection of f * on the linear space of piecewise-constant functions of the form g(x) = J(m k ) j=1 α j I{T m k ,j }(x), α j ∈ R. Recall that T i,j is defined in the tree decomposition of Section A.1. As a result, we will be able to relate the "active sets" associated to these estimators, taking advantage of the fact that the active set associated tō f k is always a union of the sets from a collection {T m k ,j , j = 1 . . . J(m k )}.
Let E 1 be the event of probability ≥ 1 − α on which f k − f * ∞,act k ≤ δ k for any k ≥ 0, where δ k = 4Ch k as defined in Algorithm 2. Assume that E 1 occurs.
The following inclusions hold (for the definition of AS k+1 , see Algorithm 2):
For all x ∈ T m k ,j , setf k (x) := 1 Π(T m k ,j )
T m k ,j f * (y)dΠ(y), and note that
where the last two inequalities follow from part 3 of assumption (A3) given in Appendix A.1, and from the definition of m k . Define τ k := max (5δ k , 4LK 1 h k ) ≤ C 5 δ k ,
to be the band of size (3/2)τ k aroundf k , and A k+1 := x ∈ act k : ∃f 1 , f 2 ∈F k+1 , sign(f 1 (x)) = sign(f 2 (x)) .
By a reasoning similar to above, we have the inclusions {x : |f * (x)| < τ k /2} ⊆Ā k+1 ⊆ {x : |f * (x)| < 5τ k /2} . (A.12)
Moreover, by the definition of τ k , we have the inequality 5δ k /2 ≤ τ k /2. Hence (A.11,A.12) imply that AS k+1 ⊆Ā k+1 . It remains to note that 1.Ā k+1 is the union of the sets from a collection {T m k ,j , j = 1 . . . J(m k )}, henceĀ k+1 ⊇ act k+1 ; 2. By (A.12) and assumption (A4),
hence proving the claim.
